Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Inclusion Criteria: 1. Age: 18 to 70 years old, no gender limitation; 2. Histopathological diagnosis of locally advanced, recurrent or metastatic HAS (pathological histomorphology and immunohistochemical diagnosis of AFP, sal-like 4(SALL4), Hep, glypican-3(GPC3), etc.); 3. Immunohistochemical(IHC) human epidermal growth factor receptor-2 (HER2) negative persons; HER2 positive is defined as IHC 3+ or IHC 2+ and fluorescence in situ hybridization(FISH)+, and FISH positive is defined as the ratio of HER2 gene copy number to chromosome 17 centromere(CEP17) signal number ≥2.0; 4. According to the RECIST 1.1 standard, at least one measurable lesion (spiral CT scan ≥10mm); 5. ECOG performance status(PS): 0-2 points; 6. The expected survival time is ≥3 months; 7. The main organs are functionally normal, without serious blood, heart, lung, liver, kidney dysfunction and immune deficiency disease. The blood test meets the following requirements; (1) Routine blood examination, which must be met (no blood transfusion within 14 days); 1. HGB≥100g/L; 2. WBC≥4.0×10\^9/L; absolute neutrophil count(ANC) ≥2.0×10\^9/L; 3. PLT≥2.0×10\^9/L; (2) The biochemical inspection must meet the following standards: <!-- --> 1. BIL≤1.5 times the upper limit of normal (ULN); 2. Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤2.5×ULN; if there is liver metastasis, ALT and AST≤5×ULN; 3. serum Cr≤1.5×ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein \<(++), or 24-hour urine protein \<1.0g; 8. The coagulation function is normal, without active bleeding and thrombosis disease; 1. International standardized ratio INR≤1.5×ULN; 2. Partial thromboplastin time APTT≤1.5×ULN; 3. Prothrombin time PT≤1.5×ULN; 9. Female subjects with fertility and male subjects whose partner is a female of childbearing age who need to take effective contraceptive measures during the study treatment period and at least 6 months after the last use of the study drug; 10. Subjects voluntarily participate in this study and sign an informed consent form (ICF); 11. Those who have good compliance and can follow up as required by the plan. Exclusion Criteria: 1. Various types of liver inflammatory diseases (especially hepatitis A, B, and C viral hepatitis active period) and other diseases that may produce AFP such as liver cirrhosis; 2. Germ cell tumors; 3. Have previously received any regimen of palliative chemotherapy for gastric cancer; 4. Have previously received apatinib treatment; 5. S-1 and/or oxaliplatin have been used in the past 6 months; 6. Those who have hypertension and cannot be reduced to the normal range after treatment with antihypertensive drugs (shrinking Pressure\>140mmHg or diastolic pressure\>90mmHg); 7. Suffering from coronary heart disease ≥2 grade, arrhythmia corrected QT interval(QTc) interval prolonged male\> 450ms, female;\>470ms) and cardiac insufficiency; 8. There are many factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic abdominal Diarrhea and intestinal obstruction, etc.); 9. Patients at risk of gastrointestinal bleeding or those with a history of gastrointestinal bleeding within 1 month; 10. Abnormal blood coagulation function (INR\>1.5×ULN, activated partial thromboplastin time(APTT)\>1.5×ULN), those with bleeding tendency; 11. Those with thrombotic diseases or receiving anticoagulant treatment; 12. Those with peripheral sensitive neuropathy with dysfunction; 13. Central nervous system metastasis; 14. Pregnant or lactating women; 15. Those who have participated in other clinical research in the past 30 days; 16. Other patients considered by the treating physician to be unsuitable for inclusion